WO2015072853A1 - Traitement de poussées d'infection par le virus de l'herpès - Google Patents

Traitement de poussées d'infection par le virus de l'herpès Download PDF

Info

Publication number
WO2015072853A1
WO2015072853A1 PCT/NL2014/050781 NL2014050781W WO2015072853A1 WO 2015072853 A1 WO2015072853 A1 WO 2015072853A1 NL 2014050781 W NL2014050781 W NL 2014050781W WO 2015072853 A1 WO2015072853 A1 WO 2015072853A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
active compound
compounds
sedative
kit
Prior art date
Application number
PCT/NL2014/050781
Other languages
English (en)
Inventor
Reinoud Jaap GAIJMANS
Original Assignee
Rjg Developments B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rjg Developments B.V. filed Critical Rjg Developments B.V.
Publication of WO2015072853A1 publication Critical patent/WO2015072853A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Definitions

  • At least one compound according to the invention that influences brain function and/or psychological state is administered sublabially or sublingually, preferably sublabially, to the subject.
  • said at least one compound is administered topically to the subject.
  • the invention provides a method for preventing or alleviating symptoms of a Herpes simplex virus infection, the method comprising administering to a subject in need thereof at least one compound that influences brain function and/or psychological state, wherein said at least one compound comprises at least one anxiolytic compound or sedative-hypnotic compound and wherein the anxiolytic or sedative -hypnotic compound comprises lormetazepam with a total dose of 0.001 - 5 mg active compound, preferably 0.01-2.0 mg active compound, or more preferably 0.1-1.0 mg active compound. In one embodiment said total dose is 0.25-0.75 mg active compound, preferably about 0.25 mg or about 0.5 mg or about 0.75 mg active compound.
  • the invention provides a method for preventing or alleviating symptoms of a Herpes simplex virus infection, the method comprising administering to a subject in need thereof at least one compound that influences brain function and/or psychological state, wherein said at least one compound comprises at least one anxiolytic compound or sedative-hypnotic compound and wherein the anxiolytic or sedative -hypnotic compound comprises chlordiazepoxide with a total dose of 0.01 - 200 mg active compound, preferably 0.1-50 mg active compound.
  • pyrazolopyridines ⁇ 2 ⁇ VDCC Blockers, 5 -HT1 A Agonists, HI Antagonists, CRH1 Antagonists, NK2 Antagonists, MCH1 antagonists, mGluR2/3 Agonists, mGluR5 NAMs, TSPO agonists, ol agonists and pharmaceutically acceptable salts, esters, hydrates, derivatives and solvates of any of these compounds.
  • a kit of parts according to the invention comprises at least one benzodiazepine compound selected from the group consisting of alprazolam, tofisopam, bromazepam, 2-keto compounds (chlorodiazepoxides, clorazepates, diazepam, ilurazepam, halazepam, prazepam and others); 3-hydroxy compounds (lorazepam, lormetazepam, oxazepam, temazepam and others); 7-nitro compounds (clonazepam, flunitrazepam, nimetazepam, nitrazepam and others), triazolo compounds (adinazolam, estazolam, triazolam and others), imidazo compounds (climazolam, loprazolam, midazolam and others), clobazam, etizolam, brotizolam, Zolpidem, zopiclon and pharmaceutically acceptable salt
  • Chlordiazepoxide Clotiazepam, Cloxazolam, Ethyl Loflazepate, Fludiazepam, Imidazenil, Ketazolam, Medazepam, Nordazepam, Pinazepam, Emylcamate,
  • kits of parts according to the invention comprises lorazepam in at least one unit dose of 0.01 - 200 mg active compound, preferably 0.1- 100 mg active compound.
  • kits of parts according to the invention comprises prazepam in at least one unit dose of 0.01 - 200 mg active compound, preferably 0.1- 100 mg active compound.
  • the present inventor has surprisingly found that outbreaks of Herpes virus infections can be suppressed or even prevented when a subject is provided with a compound that influences brain function and/or psychological state.
  • Preferred (but non-limiting) examples of such compounds are anxiolytic compounds and sedative- hypnotic compounds.
  • Such compounds that influence brain function and/or psychological state are well known in the art, but their use against Herpes outbreaks has not been described before.
  • the insight according to the present invention is, therefore, surprising, all the mere since Herpes infection is not a disease affecting brain function or psychological state.
  • herpes outbreak is defined herein as an episode wherein the latent stage of the virus infection ends and clinical manifestations of a herpes infection become apparent. A herpes outbreak thus typically begins with the prodromal and inflammation stage and ends with the healing or post-scab stage.
  • the compound that influences brain function and/or psychological state is either administered as a single dose or as multiple doses. Administration of a single dose is convenient since no dosage schedule needs to be remembered.
  • the psychological state preferably comprises at least one anxiolytic compound and/or at least one sedative -hyp no tic compound.
  • the kit of parts comprises at least two compounds selected from anxiolytic compounds and sedative -hypnotic compounds.
  • the antiviral compound of a kit of parts according to the invention is preferably selected from the group consisting of acyclovir, penciclovir, famciclovir, valaciclovir, docosanol and any combination thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des moyens et des procédés permettant de prévenir ou d'atténuer les symptômes d'une infection par le virus de l'herpès simplex, au moyen de composés qui influent sur la fonction cérébrale et/ou l'état psychologique. L'invention concerne également des kits de composants contre les poussées d'herpès.
PCT/NL2014/050781 2013-11-13 2014-11-13 Traitement de poussées d'infection par le virus de l'herpès WO2015072853A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361903433P 2013-11-13 2013-11-13
US61/903,433 2013-11-13

Publications (1)

Publication Number Publication Date
WO2015072853A1 true WO2015072853A1 (fr) 2015-05-21

Family

ID=51945984

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2014/050781 WO2015072853A1 (fr) 2013-11-13 2014-11-13 Traitement de poussées d'infection par le virus de l'herpès

Country Status (1)

Country Link
WO (1) WO2015072853A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017129801A1 (fr) * 2016-01-27 2017-08-03 Universität Zürich Utilisation de modulateurs des récepteurs gabaa pour le traitement des démangeaisons
CN107543881A (zh) * 2017-08-24 2018-01-05 广西壮族自治区食品药品检验所 苯丙氨酯片的质量控制方法
RU2781636C2 (ru) * 2016-01-27 2022-10-17 Университет Цюрих Применение модуляторов gabaa-рецептора для лечения зуда

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248503A (en) * 1992-01-03 1993-09-28 Emanuel King Rosalba Herbal dietary supplement
UA26239U (en) * 2007-05-03 2007-09-10 Ludmyla Volodymyrivn Selezneva Composition of the anti-herpetic herbal tea "product of dietetic nutrition"
US7862838B1 (en) * 2009-08-31 2011-01-04 Qing Si Zeng Composition and regimen for the treatment of herpes simplex and herpes zoster primarily by eliminating their pathogenetic conditions and taking into account both pathogenesis and etiology
WO2011148257A1 (fr) * 2010-05-27 2011-12-01 Roberto Logi Trousse de pièces pour le traitement et/ou la prévention d'ulcères cutanés

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248503A (en) * 1992-01-03 1993-09-28 Emanuel King Rosalba Herbal dietary supplement
UA26239U (en) * 2007-05-03 2007-09-10 Ludmyla Volodymyrivn Selezneva Composition of the anti-herpetic herbal tea "product of dietetic nutrition"
US7862838B1 (en) * 2009-08-31 2011-01-04 Qing Si Zeng Composition and regimen for the treatment of herpes simplex and herpes zoster primarily by eliminating their pathogenetic conditions and taking into account both pathogenesis and etiology
WO2011148257A1 (fr) * 2010-05-27 2011-12-01 Roberto Logi Trousse de pièces pour le traitement et/ou la prévention d'ulcères cutanés

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017129801A1 (fr) * 2016-01-27 2017-08-03 Universität Zürich Utilisation de modulateurs des récepteurs gabaa pour le traitement des démangeaisons
KR20180118623A (ko) * 2016-01-27 2018-10-31 우니페르지타에트 취리히 가려움증 치료를 위한 ｇａｂａａ 수용체 조절인자의 용도
US10786513B2 (en) 2016-01-27 2020-09-29 Universitat Zurich Use of GABAA receptor modulators for treatment of itch
RU2781636C2 (ru) * 2016-01-27 2022-10-17 Университет Цюрих Применение модуляторов gabaa-рецептора для лечения зуда
US11529359B2 (en) 2016-01-27 2022-12-20 Universitat Zurich Use of GABAA receptor modulators for treatment of itch
KR102482200B1 (ko) 2016-01-27 2022-12-27 우니페르지타에트 취리히 가려움증 치료를 위한 ｇａｂａａ 수용체 조절인자의 용도
CN107543881A (zh) * 2017-08-24 2018-01-05 广西壮族自治区食品药品检验所 苯丙氨酯片的质量控制方法
CN107543881B (zh) * 2017-08-24 2019-11-08 广西壮族自治区食品药品检验所 苯丙氨酯片的质量控制方法

Similar Documents

Publication Publication Date Title
Ioannides et al. European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology
EP3240538B1 (fr) Utilisation de masitinib pour le traitement d'une sous-population de patients atteints de sclérose latérale amyotrophique
AU2011268342B2 (en) Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
MX2008014841A (es) Tratamiento de agonista de melatonina.
Leung et al. Herpes labialis: an update
AU2014249530B2 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
BR112020004947A2 (pt) canabidiol transdérmico sintético para o tratamento de epilepsia focal em adultos
RU2010109359A (ru) Азитромицин для лечения кожных заболеваний
La Monaca et al. Comparative analgesic effects of single-dose preoperative administration of paracetamol (acetaminophen) 500 mg plus codeine 30 mg and ibuprofen 400 mg on pain after third molar surgery
WO2008091704A2 (fr) Traitement du syndrome de cushing et de l'autisme
WO2015072853A1 (fr) Traitement de poussées d'infection par le virus de l'herpès
RU2555765C2 (ru) Пироксикам для профилактического и терапевтического лечения герпетических инфекций
WO2010151004A9 (fr) Composition injectable contenant de l'hydroxychloroquine destinée à une administration locale pour le traitement des hémorroïdes
JP2004091473A (ja) 色素沈着改善治療薬
JP6959478B1 (ja) ポルフィリン症の予防又は治療剤
WO2015072852A1 (fr) Traitement d'éruptions de l'infection par le virus de l'herpès à l'aide de valériane
JP2003516309A (ja) 涙液分泌障害を除く外分泌障害処置剤
Fiore et al. Neuroleptic malignant-like syndrome (NMLS) in a patient with parkinson's disease resolved with rotigotine
AU2014267349A1 (en) Agent and method for treating herpes
Kaur et al. Recurrent apthous stomatitis-a review
Okolo Drugs acting on the cerebral and peripheral circulations
WO2023066330A1 (fr) Utilisation d'édaravone dans le traitement d'un trouble du spectre de l'autisme
Moore et al. Principles of pain management in dentistry
Bobeica et al. Immunologic and nonimmunologic sclerodermal skin conditions-review
Cerveró et al. 4CPS-041 Drug survival of biologic therapies for the treatment of psoriasis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14802219

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14802219

Country of ref document: EP

Kind code of ref document: A1